Long Focus Capital Management LLC Invests $28.11 Million in Elevance Health, Inc. $ELV

Long Focus Capital Management LLC purchased a new position in Elevance Health, Inc. (NYSE:ELV) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 87,000 shares of the company’s stock, valued at approximately $28,111,000. Elevance Health makes up 0.9% of Long Focus Capital Management LLC’s portfolio, making the stock its 26th biggest holding.

A number of other large investors also recently bought and sold shares of ELV. Mirabella Financial Services LLP increased its stake in shares of Elevance Health by 186.6% during the third quarter. Mirabella Financial Services LLP now owns 8,413 shares of the company’s stock valued at $2,713,000 after purchasing an additional 5,478 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Elevance Health by 21.9% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 51,669 shares of the company’s stock worth $16,692,000 after purchasing an additional 9,298 shares in the last quarter. Moore Capital Management LP grew its stake in shares of Elevance Health by 149.3% in the 3rd quarter. Moore Capital Management LP now owns 29,974 shares of the company’s stock worth $9,685,000 after buying an additional 17,953 shares during the last quarter. Loews Corp grew its stake in shares of Elevance Health by 107.5% in the 3rd quarter. Loews Corp now owns 110,000 shares of the company’s stock worth $35,543,000 after buying an additional 57,000 shares during the last quarter. Finally, Larson Financial Group LLC increased its position in Elevance Health by 9.3% during the 3rd quarter. Larson Financial Group LLC now owns 784 shares of the company’s stock valued at $253,000 after buying an additional 67 shares in the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Price Performance

Shares of NYSE ELV opened at $291.94 on Tuesday. The firm has a market cap of $64.43 billion, a P/E ratio of 11.62, a PEG ratio of 1.61 and a beta of 0.51. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The company has a 50 day moving average of $336.82 and a 200 day moving average of $334.32.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.10 by $0.23. The business had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company’s revenue was up 9.6% compared to the same quarter last year. During the same period last year, the business posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 2.4%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s payout ratio is 27.39%.

Analyst Upgrades and Downgrades

ELV has been the subject of a number of recent research reports. TD Cowen reiterated a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. Sanford C. Bernstein reduced their price target on Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Royal Bank Of Canada downgraded Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target for the company. in a report on Tuesday, February 3rd. Morgan Stanley lowered their price target on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 17th. Finally, Robert W. Baird upped their price target on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Twelve equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $387.40.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.